We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unveiling Vertex (VRTX) Q1 Outlook: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Vertex Pharmaceuticals (VRTX - Free Report) to post quarterly earnings of $4.10 per share in its upcoming report, which indicates a year-over-year increase of 34.4%. Revenues are expected to be $2.56 billion, up 7.8% from the year-ago quarter.
The current level reflects an upward revision of 0.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Vertex metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus estimate for 'Revenues by Product- Trikafta/Kaftrio' stands at $2.41 billion. The estimate suggests a change of +14.7% year over year.
Analysts' assessment points toward 'Revenues by Product- Kalydeco' reaching $103.11 million. The estimate indicates a change of -17.5% from the prior-year quarter.
Analysts forecast 'Revenues by Product- Orkambi' to reach $66.34 million. The estimate indicates a change of -45.9% from the prior-year quarter.
It is projected by analysts that the 'Revenues by Product- Symdeko' will reach $22.26 million. The estimate points to a change of -27.3% from the year-ago quarter.
The consensus among analysts is that 'Geographic Revenues- United States' will reach $1.56 billion. The estimate indicates a change of +11.2% from the prior-year quarter.
Vertex shares have witnessed a change of -4.1% in the past month, in contrast to the Zacks S&P 500 composite's -4.1% move. With a Zacks Rank #3 (Hold), VRTX is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unveiling Vertex (VRTX) Q1 Outlook: Wall Street Estimates for Key Metrics
Wall Street analysts expect Vertex Pharmaceuticals (VRTX - Free Report) to post quarterly earnings of $4.10 per share in its upcoming report, which indicates a year-over-year increase of 34.4%. Revenues are expected to be $2.56 billion, up 7.8% from the year-ago quarter.
The current level reflects an upward revision of 0.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some Vertex metrics that are commonly tracked and projected by analysts on Wall Street.
The consensus estimate for 'Revenues by Product- Trikafta/Kaftrio' stands at $2.41 billion. The estimate suggests a change of +14.7% year over year.
Analysts' assessment points toward 'Revenues by Product- Kalydeco' reaching $103.11 million. The estimate indicates a change of -17.5% from the prior-year quarter.
Analysts forecast 'Revenues by Product- Orkambi' to reach $66.34 million. The estimate indicates a change of -45.9% from the prior-year quarter.
It is projected by analysts that the 'Revenues by Product- Symdeko' will reach $22.26 million. The estimate points to a change of -27.3% from the year-ago quarter.
The consensus among analysts is that 'Geographic Revenues- United States' will reach $1.56 billion. The estimate indicates a change of +11.2% from the prior-year quarter.
View all Key Company Metrics for Vertex here>>>
Vertex shares have witnessed a change of -4.1% in the past month, in contrast to the Zacks S&P 500 composite's -4.1% move. With a Zacks Rank #3 (Hold), VRTX is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>